To identify the following items through the post marketing surveillance under routine clinical practice after marketing authorization of Brilinta Tablet: the occurrence of unrevealed Serious Adverse Events (SAEs), current status of occurrence of Adverse Events (AEs), the factors that may influence safety and efficacy of the drug.

A Post Marketing Surveillance to evaluate the safety and efficacy of Brilinta

Inclusion Criteria:

• Patients with Acute Coronary Syndromes
• Patients who are taking ticagrelor and ASA daily(75-150mg), or Patients who are taking ticagrelor only(In the case that the patients have contraindication with ASA. Contraindication should be recorded in accordance with local PI on CRFs)
• Patients who have signed the Data release consent form prior to enrollment in this surveillance

Exclusion Criteria:

• Patients with hypersensitivity to ingredients of this drug or with moderate or severe hepatic impairment or with medical history of intracranial hemorrhage
• Patients with pathological hemorrhage at the time of administration
• Patients being administrated strong CYP3A4 inhibitors

Patients who take Brilinta according to the local approval condition